HIV Research Centre

King's College Hospital is the leading research centre in the UK for HIV-associated kidney disease. Our areas of interest include:

  • the clinical epidemiology of HIV-associated kidney disease and kidney transplantation in HIV infection
  • the effects of antiretroviral therapy on the kidney
  • bone disease.

The centre also takes part in studies of liver disease, viral hepatitis and liver transplantation.

Dr Frank Post, HIV research lead
Lucy Campbell, research manager
Tel: 020 7848 5776
Fax: 020 7848 5769

Research studies

We conduct a number of clinical trials and observational cohort studies in which patients are encouraged to participate. If you are interested in taking part in any of the following clinical trials or observational studies, or would like more information, please email the research team at:

Clinical trials – currently recruiting

  • TAILoR: A study examining the effects of Telmisartan, an angiotensin-receptor blocker, on insulin resistance in HIV positive patients; patients stable on antiretroviral therapy will receive Telmisartan for 48 weeks.
  • SUPA: An interventional study aimed at improving adherence to antiretroviral therapy in those starting antiretroviral therapy.
  • GS-0140: An intensive study examining the effects of four antiretroviral regimens on kidney function; the study involves six 10-hour visits and participants will receive £2,000 for their effort.
  • TMC-3013: A switch study for patients stable on Truvada and a protease inhibitor; participants will receive a novel single tablet regimen (containing tenofovir, emtricitabine, darunavir and cobicistat).

Observational studies – currently recruiting

  • SUPA: A short questionnaire to assess risk factors for non-adherence to antiretroviral therapy.
  • POPPY: Pharmacokinetics and clinical observations in people over 50. This study examines the effects of ageing and HIV infection on health.
  • PARTNER: A Europe-wide study for HIV positive men and their HIV negative male partners designed to learn more about the risks of HIV transmission.
  • SEROCONVERTORS: A natural history study of patients with a known (approximate) date of acquiring HIV infection.
  • aMASE: Advancing Migrant Access to Health Services in Europe. This study examines barriers to healthcare for migrants living in England.
  • Genetic of drug toxicity: This study aims to identify genetic risk factors for drug hypersensitivity.
  • IDEA: Evaluating the role of novel diagnostics in patients suspected to have active tuberculosis.
  • Immune profiling of patients with tuberculosis or lymphoma.
  • CHIC Bioresource: Establishment of a bioresource for future genetic studies.

Funding sources

  • NIHR
  • Industry: Gilead Sciences, Janssen, ViiV Healthcare, Merck


For further information, refer to our full listing of peer-reviewed publications.